Back to Directory
Last Updated: 08/06/2026
STORM Therapeutics
Cambridge
Founded 2015
First-in-class small molecule inhibitors of RNA-modifying enzymes
STORM Therapeutics is a clinical-stage biotechnology company pioneering the field of RNA epigenetics, developing small molecule inhibitors of RNA-modifying enzymes as a new class of cancer treatment.
Its lead programme STC-15, a METTL3 inhibitor, was the first RNA-modifying enzyme inhibitor to enter human clinical trials and is currently in a Phase 1b/2 combination study in solid tumours.
The company's platform spans over 300 RNA-modifying enzyme targets across oncology, inflammation, CNS, and infectious disease.